FDA Move Opens Door to Biosimilar Insulins, Other Biologics FDA Move Opens Door to Biosimilar Insulins, Other Biologics

In a historic shift, FDA transitions regulatory pathway for insulin and other biologics, meaning products deemed ' biosimilar ' will be able to compete more easily with brands, in theory lowering prices.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Diabetes & Endocrinology News Source Type: news